Otsuka Pharmaceutical and H. Lundbeck, both being big pharma companies, outlined co-promotion plans and summarized the overall progress in their pharma partnering at a session in Japan with representatives from domestic and international media organizations
The companies announced that ABILIFY MAINTENA (aripiprazole), an extended-release injectable suspension for the treatment of schizophrenia will start becoming available in the U.S. market on March 18.
ABILFY MAINTENA was approved by the U.S. Food and Drug Administration (FDA) on February 28 for the treatment of schizophrenia.
ABILIFY MAINTENA and ABILIFY contain the molecule aripiprazole, which is a partial agonist at the D2 dopamine receptor and which offers a unique mechanism of action for the treatment of schizophrenia. ABILIFY MAINTENA has been shown in clinical studies to reduce relapses in schizophrenia in comparison to placebo and will offer the efficacy and safety profile of the oral formulations of ABILIFY in a once-monthly formulation.
The big pharma partnering provides Lundbeck with the rights to promote all formulations of ABILIFY that are currently being marketed, sold and distributed by Otsuka in the European Union including the swallowable tablet, oral solution, orally-disintegrating tablet and the IM rapid injectable. Lundbeck will promote ABILIFY Tablets in first position to target physicians.
For further deal information visit Current Agreements (subscription required)
Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies
Report: Partnering Deals and Alliances with Otsuka
Report: Partnering Deals and Alliances with Lundbeck
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View:Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk